0314

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

I want to receive an alert when the next issue is available online

Articles featured in this issue

Business & Regulation Business Practice

Big Bad Pharma?

12/01/2014 | Charlotte Barker

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Manufacture Small Molecules

The Final Frontier?

12/01/2014 | Stephanie Vine

The Galactic Grant Competition encourages companies to use the International Space Station for pharmaceutical R&D

Business & Regulation Business Practice

Access All Areas

12/01/2014 | Stephanie Vine

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Business & Regulation Drug Discovery

Battle of the Superbugs

12/01/2014 | Stephanie Vine

Can phage endolysins revolutionize the way bacterial infections are treated – and prevent drug resistance?

Business & Regulation

Endolysins Vs MRSA

12/02/2014 | Stephanie Vine

What is an endolysin? We spoke with Bjorn Herpers from the Regional Public Health Laboratory Kennemerland, Haarlem, in the Netherlands to find out.

Business & Regulation Business Practice

Care to ‘Patent Dance’?

12/01/2014 | Stephanie Vine

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

Business & Regulation Standards & Regulation

Regulators Target Ebola

12/01/2014 | Stephanie Vine

Will FDA fast review and voucher incentives make a difference?

Discovery & Development Drug Delivery

Dosing to Circadian Rhythm

12/01/2014 | Stephanie Vine

Could medicines be made more effective with better timing?

Business & Regulation Standards & Regulation

Making European Regulations Work

12/02/2014 | Stephanie Vine

Pathways designed to bring medicines to market faster in Europe are not delivering the goods

Manufacture Small Molecules

Side Effects and Supercomputers

12/02/2014 | Stephanie Vine

A group of researchers have used supercomputers to link proteins to drug side effects.

Manufacture Biosimilars

The Monoclonal Milestone

12/01/2014 | Carsten Brockmeyer

The launch of the world’s first biosimilar monoclonal antibody was a big step forward from a regulatory and scientific standpoint.

Manufacture Small Molecules

Calculate – Don’t Estimate – Drug Development Costs

12/01/2014 | Ayman Chit

Researchers estimate the cost of drug development at over $1 billion, while others say it’s less than $100 million. Who’s right?

Business & Regulation Business Practice

Sharing Data – and Knowledge

12/01/2014 | Steve Thomas

How to use a knowledge repository that doesn’t retire or leave you for a competitor.

Discovery & Development Formulation

What About the Kids?

12/03/2014 | Jenny Walsh

Making medicines for pediatrics adds a whole new dimension to the challenges of formulation and drug delivery

Manufacture Bioprocessing - Upstream & Downstream

Pass Me a Bottle Opener

12/01/2014 | Jaime Marach

Can a new generation of chromatography techniques and technologies get things moving again?

Manufacture Standards & Regulation

Safety First - Sizing Up Biologics Side Effects

12/02/2014 | Catherine Akers

Biologic medicines present unique challenges for pharmacovigilance. And with biosimilars hitting the market, life just got more complicated.

Discovery & Development Small Molecules

Electrifying R&D Acceleration

12/02/2014 | Mark R. Taylor, Susana Da Silva Torres

Electrochemical reaction cells are finding new applications in the pharma R&D lab that could offer big time and cost savings.

Business & Regulation Business Practice

Our Unholy Alliance

12/02/2014 | Lee DesRosiers

Science and business: tenacious partners in a shaky marriage or eternally bound nonidentical twins?

Business & Regulation Small Molecules

United Science Stands

12/02/2014

Sitting Down With… William Chin, Executive Vice President, Scientific and Regulatory Affairs, Pharmaceutical Research and Manufacturers of America (PhRMA).